Lupus & antiphospholipid syndrome
Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls
Authors' conclusion
Half of APS patients develop new atherosclerotic plaques over a 7-year follow-up, having a three-times higher risk versus HC. Concomitant SLE and number of traditional CVRFs are associated with plaque progression
Study context
- Population
- Age- and sex-matched patients with thrombotic antiphospholipid syndrome (APS), diabetes mellitus (DM) and healthy controls (HC) who underwent baseline carotid and femoral ultrasound64 APS, 58 DM, 66 HC re-evaluated
- Participants
- 86 / 86 / 86
- Exposure
- Thrombotic APS vs DM vs healthy controls
- APSn = 86
- DMn = 86
- HCn = 86reference
- Outcome
- Atherosclerotic plaque progression (new plaque) on ultrasound
- Follow-up
- 7 years
Methodological detailsage- and sex-matched, 7-year follow-up, carotid and femoral ultrasound
- Age- and sex-matched
- 7-year follow-up
- Carotid and femoral ultrasound
Main finding
As reported in the abstract
New plaque
Odds ratio
3.07
P = 0.007
APS vs HC
Odds ratio
2.25
P = 0.047
APS vs DM
Observational data: associations, not effects.
Further findings
Determinants of plaque progression in APS (multivariate analysis) · 7-year follow-up
| OR | P value | |
|---|---|---|
| SLE co-existenceAPS group only | 7.78 | P = 0.005 |
| Number of CVRFsAPS group only | 3.02 | P = 0.002 |
| Outcome | OR | P value |
|---|---|---|
| Sustained low-density lipoprotein target attainment and plaque progression risk in APS · 7-year follow-upReduced plaque progression risk | 0.34 | P = 0.021 |
- Determinants of plaque progression in APS (multivariate analysis): adjusted for disease-related parameters and CVRF-related medications
- Determinants of plaque progression in APS (multivariate analysis): adjusted for disease-related parameters and CVRF-related medications
Original publication
Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls. Rheumatology (Oxford). Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →